New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic
Written by Black Hot Fire Network on July 24, 2023
– Biktarvy Evaluated in a Diverse Range of People With HIV, Including Pregnant Women and Pediatric Populations –
– 96-Week Data from ALLIANCE Trial Show Durability of Biktarvy in Adults With HIV and HBV Coinfection –
FOSTER CITY, Calif.--(BUSINESS WIRE)--
Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from multiple studies reinforcing Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) as a treatment option for a broad range of people with HIV. The latest findings include key insights into the treatment of virologically suppressed pregnant women . . .
